More, almost certain deletions, from the snake-pit
Post# of 72440
(Total Views: 893)
Posted On: 08/16/2017 1:36:25 PM
More, almost certain deletions, from the snake-pit. De-bunking debunker-1!
Ah you parse your words so carefully young serpent. BigK didn't say he RECEIVED his PhD FROM Harvard (Dana Farber), he said he received a PhD while WORKING at Dana Farber under Dr. Frei! here's a little bio info for you! Not too shabby for a "veterinarian from the Caribbean"?
Dr. Menon was originally trained as a veterinary surgeon. He was Director of Agriculture for Cayman Islands, in the British Caribbean during 1978-1981. Thereafter he came to the Dana Farber Cancer Research Institute and obtained a PhD in Pharmacology in 1984 from Kerala University. He worked under the direction of Nobel Laureate Dr. Tom Frye. His PhD work involved anti-folate therapy of various cancers, which has led to the extremely important drugs. He was Research Scientist at Dana Farber between 1985 to 1990. He was Scientist, In Vivo Research (Cancer), at Bayer Pharmaceuticals (Miles Laboratories) during 1991-1993. He had his own veterinary oncology and drug development consultancy practice during 1994. Thereafter, he was Group Leader, Cancer In Vivo Research and Clinical Development, at Eli Lilly and Company during 1995-2001. He contributed to the development of the anticancer drugs Cryptophycin and the blockbusters, Gemzar and Alimta. He also helped developed another seven compounds at Lilly which are in late clinical phases at present. He has also contributed to the development of an anti-infective drug by Nexus Pharmaceuticals.
Dr. Menon won the Employee of the Year, President's Award at Eli Lilly for 1999. Later, he was the Director of Operations for the ALS Therapy Development Foundation during 2001-2002 (ALS is acute lateral sclerosis, a disease related to Lou Gehrig's Syndrome). He is a Founder and Board Member of KARD Scientific, Cambridge, MA; KARD Inc., Wilmington, MA; as well as KARD Scientific India, Bangalore, India and KARD Medics, Mumbai, India. He is a Director of Biological Supplies, New York, NY. He was a Member of the Scientific Advisory Board of Nexus Pharmaceuticals, Philadelphia, PA and TheraCour Pharma, Inc., West Haven, CT. He is Distinguished Scientist and Scientific Diplomat for GPC-Biotech, Germany. Dr. Menon is a Toxicologist and a Member of the American Association of Toxicology. He holds a VMD from Triniti University, Peru, and MRCS from Royal University of Copenhagen. He is a practicing veterinary surgeon, licensed in various countries.
Dr. Menon participated in the development of 8 International and 3 US patents. He has been responsible for 7 FDA approved drugs, 3 of which are blockbusters. While at Harvard, he conducted pre-clinical studies on the important anti-HIV drug, AZT. He is well known for his grasp of scientific and regulatory matters in taking a compound from the Chemist's bench to FDA approval. He is regularly invited to lecture across the globe on the drug development process and the regulatory landscape.
Ah you parse your words so carefully young serpent. BigK didn't say he RECEIVED his PhD FROM Harvard (Dana Farber), he said he received a PhD while WORKING at Dana Farber under Dr. Frei! here's a little bio info for you! Not too shabby for a "veterinarian from the Caribbean"?
Dr. Menon was originally trained as a veterinary surgeon. He was Director of Agriculture for Cayman Islands, in the British Caribbean during 1978-1981. Thereafter he came to the Dana Farber Cancer Research Institute and obtained a PhD in Pharmacology in 1984 from Kerala University. He worked under the direction of Nobel Laureate Dr. Tom Frye. His PhD work involved anti-folate therapy of various cancers, which has led to the extremely important drugs. He was Research Scientist at Dana Farber between 1985 to 1990. He was Scientist, In Vivo Research (Cancer), at Bayer Pharmaceuticals (Miles Laboratories) during 1991-1993. He had his own veterinary oncology and drug development consultancy practice during 1994. Thereafter, he was Group Leader, Cancer In Vivo Research and Clinical Development, at Eli Lilly and Company during 1995-2001. He contributed to the development of the anticancer drugs Cryptophycin and the blockbusters, Gemzar and Alimta. He also helped developed another seven compounds at Lilly which are in late clinical phases at present. He has also contributed to the development of an anti-infective drug by Nexus Pharmaceuticals.
Dr. Menon won the Employee of the Year, President's Award at Eli Lilly for 1999. Later, he was the Director of Operations for the ALS Therapy Development Foundation during 2001-2002 (ALS is acute lateral sclerosis, a disease related to Lou Gehrig's Syndrome). He is a Founder and Board Member of KARD Scientific, Cambridge, MA; KARD Inc., Wilmington, MA; as well as KARD Scientific India, Bangalore, India and KARD Medics, Mumbai, India. He is a Director of Biological Supplies, New York, NY. He was a Member of the Scientific Advisory Board of Nexus Pharmaceuticals, Philadelphia, PA and TheraCour Pharma, Inc., West Haven, CT. He is Distinguished Scientist and Scientific Diplomat for GPC-Biotech, Germany. Dr. Menon is a Toxicologist and a Member of the American Association of Toxicology. He holds a VMD from Triniti University, Peru, and MRCS from Royal University of Copenhagen. He is a practicing veterinary surgeon, licensed in various countries.
Dr. Menon participated in the development of 8 International and 3 US patents. He has been responsible for 7 FDA approved drugs, 3 of which are blockbusters. While at Harvard, he conducted pre-clinical studies on the important anti-HIV drug, AZT. He is well known for his grasp of scientific and regulatory matters in taking a compound from the Chemist's bench to FDA approval. He is regularly invited to lecture across the globe on the drug development process and the regulatory landscape.
(4)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼